Table 3.

Markers of heterogenic CSCs.

Marker	Tumour Initiating Capacity	Drug Resistance	Metastasis Initiating Capacity
CD44	Prostate cancer (100)	Prostate cancer (100) Ovarian cancer (92)	Prostate cancer (100) Ovarian cancer (92)
CD133+	Pancreatic cancer (101)	Colorectal cancer (102)	Pancreatic cancer (101)
ABCG2	Colon cancer (103)	Colon cancer (103) Esophageal squamous cancer cells (104)	Esophageal squamous cancer cells (104)
CD49f	Triple negative breast cancer (105)	Triple negative breast cancer (105)	Human cervical cancer (106)
CD66			Human cervical cancer (106) (107),
OCT4	Gastric cancer (108) Breast cancer (76)	Gastric cancer (108) Breast cancer (76)	Gastric cancer (108)
SOX2	Gastric cancer (108)	Gastric cancer (108)	Gastric cancer (108)
NANOG	Breast cancer (76)	Breast cancer (76)	Urinary bladder cancer (109)
ALDH1A1	Oral cancer (45)	Ovarian cancer (110)	Breast cancer (78)

Different markers are reported to denote tumor initiating cells, drug-resistant CSCs or metastasis-initiating cells.